Purple Biotech Ltd
PPBT
View Detailed Chart
0.818USD
+0.077+10.45%
Close 11/07, 16:00（ET）Quotes delayed by 15 min
464.67MMarket Cap
LossP/E TTM
Intraday
1m
30m
1h
D
W
M
D
Today
+10.45%
5 Days
+4.24%
1 Month
+42.23%
6 Months
-63.05%
Year to Date
-82.55%
1 Year
-70.88%
View Detailed Chart
TradingKey Stock Score of Purple Biotech Ltd
Currency: USD Updated: 2025-11-07Key Insights
The company's fundamentals are relatively weak. Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Buy. Despite a strong stock market performance, the company shows strong fundamentals and technicals, which don't support the current strong trend. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Purple Biotech Ltd's Score
Support & Resistance
No Data
Score Analysis
Current score
Previous score
Analyst Rating
Based on
1
analysts
Buy
Current Rating
34.000
Target Price
+4054.45%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Purple Biotech Ltd Highlights
StrengthsRisks
Purple Biotech Ltd, formerly Kitov Pharma Ltd, is an Israel-based clinical-stage company that develops drugs that overcome tumor-immune evasion and drug resistancetreat pain. Main products of the Company is NT-219 i CM-24. CM-24 is a monoclonal antibody blockin and NT-219 is a small molecule bi-specific inhibitor of two key cancer resistance pathways. The Company is also the owner of Consensi, a fixed-dose combination of celecoxib and amlodipine besylate, for the simultaneous treatment of osteoarthritis pain and hypertension.
Overvalued
The company’s latest PE is -1.61, at a high 3-year percentile range.
Institutional Buying
The latest institutional holdings are 355.08K shares, increasing 21.81% quarter-over-quarter.
Held by CI Select Canadian Equity Fund
Star Investor CI Select Canadian Equity Fund holds 0.00 shares of this stock.
Purple Biotech Ltd News
More news coming soon, stay tuned...
Financial Indicators
EPS
No Data
Total revenue
No Data
Purple Biotech Ltd Info
Purple Biotech Ltd, formerly Kitov Pharma Ltd, is an Israel-based clinical-stage company that develops drugs that overcome tumor-immune evasion and drug resistancetreat pain. Main products of the Company is NT-219 i CM-24. CM-24 is a monoclonal antibody blockin and NT-219 is a small molecule bi-specific inhibitor of two key cancer resistance pathways. The Company is also the owner of Consensi, a fixed-dose combination of celecoxib and amlodipine besylate, for the simultaneous treatment of osteoarthritis pain and hypertension.
Ticker SymbolPPBT
CompanyPurple Biotech Ltd
CEOMr. Gil Efron, CPA
Websitehttps://purple-biotech.com/
Related Instruments
-1.43%
-0.22%
+0.06%
+0.97%
-0.17%
+0.59%
+1.46%
-1.83%
-3.70%
+0.06%
+0.34%
-0.77%
-1.63%
+0.16%
-1.00%
+0.58%
0.00%
+1.65%
+0.50%
+0.57%Popular Symbols
